Talk About Expensive Lawsuits. Law.com reports that "GlaxoSmithKline Faces Second Antitrust Suit Over Alleged 'Sham' Patent." From the article: "Antitrust claims that have already cost GlaxoSmithKline $175 million to settle are potentially even more expensive now that a federal judge in Philadelphia has green-lighted a second suit that alleges nearly identical claims."